AKAlexander Kiefer

Alexander Kiefer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander Kiefer has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Michael Kabesch

    Department of Paediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Regensburg, Germany

    3 shared publications
  • Andreas Ambrosch

    Krankenhaus Barmherzigen Brader Regensburg, Inst Lab Med Microbiol & Hosp Hyg, Regensburg, Germany

    2 shared publications
  • Clemens Behrens

    Pediatrician's office Dr. med. Clemens Behrens/Dr. med. Marc Bohn/ Dr. med. Carolin Lorentzen, Hannover, Germany

    2 shared publications
  • Frank Eberhardt

    Capnetz Stiftung, Hannover, Germany

    2 shared publications
  • Martin Rosewich

    Paediatrician's office PD Dr. med. Martin Rosewich, Oberursel, Germany

    2 shared publications
  • Martin Wetzke

    Hannover Medical School, Hannover, Germany

    2 shared publications

Latest Publications

  • Open Access

    Primary care respiratory syncytial virus disease characteristics in infants and young children in Germany: data from the prospective pediatric airway pathogen incidence surveillance network, 2021-2023

    by Alexander Kiefer, David Twardella, Jessica Bähre, Clemens Behrens, Thomas Buck, Frank Eberhardt, Mathieu Bangert, Rolf Kramer, Andrea Gerber, Martin Rosewich, et al.


  • Open Access

    Alterations of bile acid composition in children with cystic fibrosis compared to healthy controls

    by Felix Escher, Gerhard Liebisch, Michael Melter, Thomas S. Weiss, Birgit Knoppke, Alexander Kiefer

  • Open Access

    Disease Spectrum of Human Metapneumovirus Infections in Infants and Young Children: Data From a Prospective Multicenter Study in Germany

    by Johannes Borgmann, Cordula Koerner-Rettberg, Alexander Kiefer, Michael Dördelmann, Sven Armbrust, Markus Hufnagel, Benedikt Spielberger, Michael Lorenz, Sebastian Bode, Axel Teichmann, et al.

    Background: Human metapneumovirus (hMPV) is a significant respiratory pathogen in infants and young children. Although most infections present as nonsevere cases in outpatient settings, severe courses can lead to hospitalization. Few potential risk factors for hospitalization have already been identified, but studies comparing the clinical presentation of children with hMPV in inpatient versus outpatient settings are lacking. Methods: This retrospective analysis used data from the Pediatric Airway Pathogen Incidence study, a multicenter surveillance study of lower respiratory tract infections, conducted in Germany during winter seasons 2021/22 and 2022/23 (weeks 40–17 each season). We compared 102 hospitalized and 114 outpatient pediatric cases with laboratory-confirmed hMPV infection after excluding coinfections with respiratory syncytial virus. Detailed clinical and demographic data were collected. Results: Hospitalized patients were significantly younger (median age 9 vs. 14 months, P = 0.003) than outpatients. Prematurity was notably higher in severe cases (25% vs. 6.2%, P < 0.001), and extreme prematurity (gestational age <28 weeks) was present only in hospitalized patients. Hospitalized cases were independently associated with a history of recurrent wheezing, but not with neonatal invasive and noninvasive respiratory support, inhalative steroids and bronchopulmonary dysplasia. On clinical examination, hospitalized children more often exhibited wheezing, crackles, tachypnea, hypoxemia and reduced fluid intake. Hypoxemia in hMPV was independently associated with gestational age at birth, but not with age at diagnosis. Conclusion: The clinical presentation of hMPV in hospitalized young children differed from that observed in outpatient settings. We identified multiple factors that were independently associated with hMPV-related hospitalization.


  • Open Access

    Timely Association of RSV Hospitalisation Waves in Children with the Detection of SARS-CoV-2 in the General Population in Eastern Bavaria

    by Alexander Kiefer, Andreas Ambrosch, Benedikt M. J. Lampl, Fritz Schneble, Kai Rubarth, Stefan Vlaho, Matthias Keller, Michael Kabesch

    Background: The Respiratory Syncytial Virus (RSV) season of 2023/2024 was conspicuously different from previous seasons, with an abrupt decrease in hospitalisation rates at the peak of the season, leading to two lower peaks instead of the expected one high peak of hospitalisations. Thus, we investigated whether there was an interference with other virus infection waves in the course of that RSV season. Methods: We analysed RSV seasons since 2016 in children who were hospitalised due to an RSV infection in Eastern Bavaria and investigated epidemiological features of RSV seasons after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic at local, regional, and national levels. Results: Analysing patterns of four RSV seasons prior to and three seasons after the SARS-CoV-2 pandemic, we found that the paediatric RSV hospitalisation wave of the 2023/2024 season was weaker and less pronounced than expected. When we compared detailed local, regional, and national surveillance data of other viral infections, we found that paediatric RSV hospitalisation waves were anticyclical to SARS-CoV-2 infection waves, but not to rhinovirus or influenza waves in the general population. Discussion: Our data suggests that concomitant SARS-CoV-2 infection waves in the general population may disrupt infection chains of RSV in children and, thus, decrease RSV-associated hospitalisation. This factor should be taken into account when assessing the effects of the upcoming RSV prophylaxis in the future.


  • Button Battery Ingestions cause the Majority of Severe Complications

    by Alexander Kiefer, Uta Duppel, Alexander Schützenmeier, Thomas Lang, Jochen Kittel, Michael Kabesch, Sebastian Kerzel

    Background Foreign body ingestion in children is a clinically important reason for presentation to the emergency department. The individual outcome ranges from benign spontaneous courses to severe complications. Fatal outcomes occur rarely and complications are related to patient’s age as well as type and location of the foreign body. The aim of our present study was to evaluate the outcome of children and adolescents with foreign body ingestion with a focus on complications, which mainly occurred after button battery ingestion. Methods We reviewed medical records of patients between 0 and 18 years of age who had presented to the paediatric emergency department of our hospital with suspected foreign body ingestion between January 2011 and March 2021 (123 months). Clinical, imaging, and endoscopic data as well as treatment modalities were analysed. Results In the ten10 year period under review, a total of 1,162 children and adolescents (6 months – 18 years) presented to our emergency room with suspected foreign body ingestion. Among those, 398 ingestions (34%) could be verified radiologically and/or endoscopically, while in the remaining 764 cases (66%) the suspicion could not be confirmed. The majority of patients with verified ingestion (n=324; 81%) presented with ingestion of a metallic foreign body. We observed 55 cases with verified ingestion of a button battery. Five of these cases had severe complications, with a near-fatal course in two patients who developed an oesophageal-tracheal fistula. Conclusion In contrast to all other ingestions of foreign bodies in children, button battery ingestions lead to mucosal damage and severe complications in a significant number of children.


  • Open Access

    DMBT1 is upregulated in cystic fibrosis, affects ciliary motility, and is reduced by acetylcysteine

    by Alexander Kiefer, Erika Plattner, Renate Ruppel, Christel Weiss, Zhe Zhou-Suckow, Marcus Mall, Marcus Renner, Hanna Müller

    Background: Cystic fibrosis (CF) is the most common genetic disorder in the Caucasian population. Despite remarkable improvements in morbidity and mortality during the last decades, the disease still limits survival and reduces quality of life of affected patients. Moreover, CF still represents substantial economic burden for healthcare systems. Inflammation and infection already start in early life and play important roles in pulmonary impairment. The aim of this study is to analyze the potential role of DMBT1, a protein with functions in inflammation, angiogenesis, and epithelial differentiation, in CF. Results: Immunohistochemically DMBT1 protein expression was upregulated in lung tissues of CF patients compared to healthy controls. Additionally, pulmonary expression of Dmbt1 was approximately 6-fold increased in an established transgenic mouse model of CF-like lung disease (ENaC tg) compared to wild-type mice as detected by qRT-PCR. Since acetylcysteine (ACC) has been shown to reduce inflammatory markers in the airways, its potential influence on DMBT1 expression was analyzed. A549 cells stably transfected with an expression plasmid encoding the largest (8kb) DMBT1 variant (DMBT1+ cells) or an empty vector control (DMBT1- cells) and incubated with ACC both showed significantly reduced DMBT1 concentrations in the culture medium (p = 0.0001). To further elucidate the function of DMBT1 in pulmonary airways, respiratory epithelial cells were examined by phase contrast microscopy. Addition of human recombinant DMBT1 resulted in altered cilia motility and irregular beat waves (p < 0.0001) suggesting a potential effect of DMBT1 on airway clearance. Conclusions: DMBT1 is part of inflammatory processes in CF and may be used as a potential biomarker for CF lung disease and a potential tool to monitor CF progression. Furthermore, DMBT1 has a negative effect on ciliary motility thereby possibly compromising airway clearance. Application of ACC, leading to reduced DMBT1 concentrations, could be a potential therapeutic option for CF patients.


  • COVID-19 bei Kindern und Jugendlichen mit chronischen Lungenerkrankungen

    by A. Kiefer, S. Kerzel

    Zusammenfassung Hintergrund Kinder und Jugendliche mit chronischen Lungenerkrankungen standen zu Beginn der SARS-CoV-2-Pandemie im Fokus der Aufmerksamkeit. Mangels epidemiologischer Daten und klinischer Erfahrung war zu befürchten, dass Kinder mit respiratorischen Vorerkrankungen – ähnlich wie im Erwachsenenalter – eine Risikogruppe für besonders schwere Verläufe von COVID-19 darstellen. Ziel der Arbeit Es erfolgen die Darstellung der aktuellen vorliegenden Daten zu dieser Patientengruppe und Schilderung der eigenen Erfahrungen anhand von 3 ausgewählten Fällen. Material und Methoden Es erfolgen die Auswertung der aktuellen (epidemiologischen) Daten, Beschreibung dreier ausgewählter Fälle und Diskussion aktueller Empfehlungen und Handlungsstrategien. Ergebnisse Die Inzidenz von COVID-19-Erkrankungen ist bei Kindern und Jugendlichen deutlich niedriger als bei Erwachsenen. Weiterhin lassen sich die bei Erwachsenen bekannten Risikofaktoren nicht einfach auf das pädiatrische Patientenkollektiv übertragen. Kinder und Jugendliche mit chronischen Lungenerkrankungen zeigen in der Mehrzahl der Fälle einen milden Verlauf einer SARS-CoV-2-Infektion. Diskussion Die insgesamt ermutigenden Erfahrungen sollten nicht darüber hinwegtäuschen, dass es auch bei Kindern und Jugendlichen zu teilweise schweren Verläufen kommt. Weiterhin können Spätfolgen wie das „pediatric inflammatory multisystem syndrome“ (PIMS) mit teilweise fatalem Ausgang auftreten. Dennoch ist darauf zu achten, dass diese vulnerable Patientengruppe nicht durch Isolationsmaßnahmen und Einschränkungen vermeidbare Schäden erleidet. Als Beispiel genannt seien hier aus Corona-Angst abgesagte Ambulanztermine, sodass Verschlechterungen der Grunderkrankung verspätet erkannt werden.


  • Open Access

    Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme

    by Alexander Kiefer, Christian Bogdan, Volker O. Melichar

    In individuals with cystic fibrosis (CF), colonization with methicillin-resistant Staphylococcus aureus (MRSA) was reported to be associated with a deterioration of pulmonary disease as reflected by an accelerated decline in lung function. Thus, an early eradication of MRSA could be beneficial in these patients. Here, we report on an intensified MRSA eradication protocol. Since 2012 a protocol for the eradication of newly acquired MRSA has been used in our CF Clinic, combining oral rifampicin and fusidic acid, inhaled vancomycin, nasal mupirocin, local antiseptic treatment and hygienic directives all of which are applied for only 7 days during an inpatient hospital stay. Since 2012 seven patients (3 male, 4 female; age range 4 to 30 years) newly acquired MRSA. In 6 of the 7 patients (86%) successful eradication of MRSA was achieved upon first treatment using the protocol described above. In one patient a second course of treatment was performed which, however, also failed to eliminate the colonizing MRSA. Our protocol led to an eradication rate of 86%. The impact of each individual component of the protocol remains to be determined.